SCHEMBL2851609

SCHEMBL2851609

COC(=O)CCc1ccc(CN)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.56
CYP4F2 P78329 2/20 0.50
CYP4A11 Q02928 2/20 0.50
EPHX2 P34913 1/20 0.49
F2RL1 P55085 1/20 0.49
ADRB2 P07550 1/20 0.48
ADRB1 P08588 1/20 0.48
TPSAB1 Q15661 3/20 0.47
IDO1 P14902 1/20 0.47
SIRT2 Q8IXJ6 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TSHR P16473 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL926987 0.98 LOXL2 (0.55) LOXL2CYP4F2CYP4A11EPHX2F2RL1
SCHEMBL11135506 0.95 LOXL2 (0.51) LOXL2CYP4F2CYP4A11EPHX2F2RL1
SCHEMBL11135481 0.92 LOXL2 (0.57) LOXL2CYP4F2CYP4A11EPHX2F2RL1
SCHEMBL22922181 0.90 CYP4F2 (0.59) CYP4F2CYP4A11EPHX2F2RL1ADRB2
SCHEMBL4832980 0.89 LOXL2 (0.53) LOXL2CYP4F2CYP4A11EPHX2TPSAB1
SCHEMBL11133337 0.89 ADRB2 (0.47) LOXL2CYP4F2CYP4A11EPHX2F2RL1
Hydrochloric Acid SCHEMBL4832972 0.87 LOXL2 (0.51) LOXL2CYP4F2CYP4A11EPHX2TPSAB1
Hydrochloric Acid SCHEMBL9265296 0.87 TAAR1 (0.50) CYP4F2CYP4A11EPHX2F2RL1ADRB2
SCHEMBL5043214 0.86 LOXL2 (0.57) LOXL2CYP4F2CYP4A11SIRT2ALDH1A1
SCHEMBL223653 0.85 CYP4F2 (0.50) CYP4F2CYP4A11EPHX2F2RL1ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022103983-A9 FLUORENYLMETHYLOXYCARBONYL AND FLUORENYLMETHYLAMINOCARBONYL COMPOUNDS, PROTEIN CONJUGATES THEREOF, AND METHODS FOR THEIR USE SUTRO BIOPHARMA, INC. (US) 2022-06-09 WO disclosed
WO-2022103983-A2 FLUORENYLMETHYLOXYCARBONYL AND FLUORENYLMETHYLAMINOCARBONYL COMPOUNDS, PROTEIN CONJUGATES THEREOF, AND METHODS FOR THEIR USE SUTRO BIOPHARMA, INC. (US) 2022-05-19 WO disclosed
WO-2020257235-A1 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS SUTRO BIOPHARMA, INC. (US) 2020-12-24 WO disclosed
WO-2020227110-A1 ANTI-BCMA ANTIBODY CONJUGATE, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF MAKING AND USING THE SAME SUTRO BIOPHARMA, INC. (US) 2020-11-12 WO disclosed
EP-1654247-B1 ALKYNYL ARYL CARBOXAMIDES MERCK SERONO SA (CH) 2010-01-20 EP disclosed
US-7589232-B2 Alkynyl aryl carboxamides LABORATORIES SERONO S.A. (CH) 2009-09-15 US disclosed
US-7589232-B2 Alkynyl aryl carboxamides LABORATORIES SERONO S.A. (CH) 2009-09-15 US disclosed
US-7465811-B2 Indoline compounds LABORATOIRES FOURNIER S.A. (FR) 2008-12-16 US disclosed
US-7402595-B2 Enzyme inhibitors with isoquinolinone structures TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-22 US disclosed
US-20080119465-A1 Novel Indoline Compounds LABORATORIES FOURNIER S.A. (FR) 2008-05-22 US disclosed
US-5256812-A Antitumor agents, cardiovascular disorders; having amidino or guandino groups HOFFMANN-LA ROCHE INC. (US) 1993-10-26 US disclosed
EP-0483667-A2 Cyclic imino derivatives, process for their preparation and drugs containing them Dr. Karl Thomae GmbH (DE) 1992-05-06 EP disclosed
US-5084466-A Anticoagulants, antiinflammatory agents, atheriosclerosis and antitumor agents HOFFMANN-LA ROCHE INC. (US) 1992-01-28 US disclosed
CN-1046902-A Process for preparing 1, 5-benzothiazepine * derivatives TANABE SEIYAKU CO (JP) 1990-11-14 CN disclosed
CN-1005150-B 1, 5-benzothiazepine * derivatives as platelet aggregation inhibitors 田道制药株式会社 1989-09-13 CN disclosed
CN-1004351-B Method for preparing selaginellin related compound with phenylene 微生物化学研究会 1989-05-31 CN disclosed
EP-0153720-B1 SPERGUALIN-RELATED COMPOUNDS HAVING A PHENYLENE GROUP, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 1988-11-09 EP disclosed
CN-85101425-A Have Si Baige Eyring allied compound of phenylene and preparation method thereof 1987-01-17 CN disclosed
US-4556735-A BACTERICIDE, ANTITUMOR AGENT ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYUKAI (JP) 1985-12-03 US disclosed
EP-0153720-A2 Spergualin-related compounds having a phenylene group, a process for their preparation and their use as medicaments MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 1985-09-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119465-A1 Novel Indoline Compounds GPR119, INSR, IRS1 LOXL2 4346/4885CYP4F2 1271/4885CYP4A11 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.